A Multi Centric, Randomized, Assessor Blind, Parallel, Phase III Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of Intas Denosumab (60 mg Single Use Vial) in Comparison to The Reference Listed Drug Prolia® (Denosumab, 60 mg Single Use Vial) in Women With Postmenopausal Osteoporosis. - NA

Trial Profile

A Multi Centric, Randomized, Assessor Blind, Parallel, Phase III Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of Intas Denosumab (60 mg Single Use Vial) in Comparison to The Reference Listed Drug Prolia® (Denosumab, 60 mg Single Use Vial) in Women With Postmenopausal Osteoporosis. - NA

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Intas Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top